Loading stock data…
TEM
$48.46-1.40 (-2.81%)
Market ClosedLast close May 11
Tempus AI, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tempus AI, Inc. in the Healthcare sector is trading at $48.46. The stock is currently near its 52-week low of $41.73, remaining 27.5% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why TEM maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$48.46
Potential Upside
5%
Whystock Fair Value$50.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$69.27+42.9%
Range$35.00 – $100.00
Fundamentals
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.65%
Volume
Today's trading volume
8.17M
Recent News
Is Tempus AI (TEM) The Best AI Healthcare Stock to Buy?
We just covered Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Tempus AI Inc. (NASDAQ:TEM) ranks #5 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks). Cathie Wood’s Stake: $446,275,249 Tempus AI Inc. (NASDAQ:TEM) is an AI healthcare play in Cathie Wood’s portfolio. It’s a healthcare diagnostics and data platform that builds large-scale […]
Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance
Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathway and blood test for Alzheimer's detection into clinical workflows. The collaboration centers on integrating the LucentAD Complete blood-based biomarker panel into Tempus's Next platform for use by neurologists. The partnership extends Tempus AI's reach beyond oncology into neurology and broader precision medicine applications. Tempus AI, trading at around $49.43 per share,...
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Employment Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6% and the actively trad
Why The Dip In TEM Stock Is A Buying Window
Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he
Tempus AI Q1 Earnings Call Highlights
Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca